Pfizer's sildenafil appeal rejected in Australia

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.257, 2000-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pfizer, for the third time, has failed to get sildenafil [`Viagra'] listed under Australia's PBS,

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 353, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Sildenafil

By Cartledge J. Eardley I.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 137-147

Informa Healthcare

Access to resources Recommend Favorite

The federal government in Australia has announced that Pfizer's atorvastatin [Lipitor] warrants a higher price than Merck & Co's simvastatin [Zocor] for Pharmaceutical Benefits Scheme (PBS) subsidy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 483, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Pfizer pulls the plug on Mylotarg

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Pfizer-Pharmacia: the postmerger

By Wiggins Phillip

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1761-1763

Informa Healthcare

Access to resources Recommend Favorite